Published in Eur J Immunol on February 01, 2001
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov (2010) 5.55
ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. J Exp Med (2008) 3.39
A coordinated change in chemokine responsiveness guides plasma cell movements. J Exp Med (2001) 3.36
Early appearance of germinal center-derived memory B cells and plasma cells in blood after primary immunization. J Exp Med (2005) 2.51
Development and migration of plasma cells in the mouse lymph node. Immunity (2010) 2.44
International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev (2013) 2.11
Chemokine receptor CCR9 contributes to the localization of plasma cells to the small intestine. J Exp Med (2004) 1.97
CXCR4 antagonism increases T cell trafficking in the central nervous system and improves survival from West Nile virus encephalitis. Proc Natl Acad Sci U S A (2008) 1.60
The intestinal chemokine thymus-expressed chemokine (CCL25) attracts IgA antibody-secreting cells. J Exp Med (2002) 1.59
Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism. J Exp Med (2006) 1.51
Early preplasma cells define a tolerance checkpoint for autoreactive B cells. J Immunol (2006) 1.41
Abnormal B-cell responses to chemokines, disturbed plasma cell localization, and distorted immune tissue architecture in Rgs1-/- mice. Mol Cell Biol (2004) 1.20
CD11c expression identifies a population of extrafollicular antigen-specific splenic plasmablasts responsible for CD4 T-independent antibody responses during intracellular bacterial infection. J Immunol (2008) 1.19
A genetic lesion that arrests plasma cell homing to the bone marrow. Proc Natl Acad Sci U S A (2003) 1.16
The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease. Immunol Rev (2003) 1.13
Alphavirus-induced encephalomyelitis: antibody-secreting cells and viral clearance from the nervous system. J Virol (2011) 0.95
Early differentiated CD138(high) MHCII+ IgG+ plasma cells express CXCR3 and localize into inflamed kidneys of lupus mice. PLoS One (2013) 0.92
The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression. Arthritis Res Ther (2012) 0.85
c-Myb is required for plasma cell migration to bone marrow after immunization or infection. J Exp Med (2015) 0.79
Plasma cell purification from murine bone marrow using a two-step isolation approach. J Immunol Methods (2007) 0.78
Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche. J Leukoc Biol (2017) 0.77
Expression Cloning and Production of Human Heavy-Chain-Only Antibodies from Murine Transgenic Plasma Cells. Front Immunol (2016) 0.75
The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature (1996) 9.25
International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev (2000) 7.17
Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med (1996) 6.36
BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med (1999) 6.27
CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med (2000) 6.06
Sites of specific B cell activation in primary and secondary responses to T cell-dependent and T cell-independent antigens. Eur J Immunol (1991) 5.38
Mechanism of antigen-driven selection in germinal centres. Nature (1990) 5.26
Lymphocyte traffic control by chemokines. Nat Immunol (2001) 4.86
A novel neutrophil-activating factor produced by human mononuclear phagocytes. J Exp Med (1988) 4.86
Antibody in the induction and inhibition of lymphocyte cytotoxicity. Transplant Rev (1972) 4.79
Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol (1998) 4.51
Resolution of granules from rabbit heterophil leukocytes into distinct populations by zonal sedimentation. J Cell Biol (1969) 4.36
Circulating immune complexes in inflammatory bowel disease. Clin Exp Immunol (1973) 4.32
Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J (1997) 4.04
T-cell receptor V beta use predicts reactivity and tolerance to Mlsa-encoded antigens. Nature (1988) 4.04
CCR5 is characteristic of Th1 lymphocytes. Nature (1998) 3.92
Purification and amino acid sequencing of NAF, a novel neutrophil-activating factor produced by monocytes. Biochem Biophys Res Commun (1987) 3.77
A molecular basis for MHC class II--associated autoimmunity. Science (1988) 3.75
Biochemical and morphological characterization of azurophil and specific granules of human neutrophilic polymorphonuclear leukocytes. J Cell Biol (1974) 3.71
HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med (1997) 3.71
B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med (1998) 3.60
Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes. J Biol Chem (1994) 3.50
Ion channels in human neutrophils activated by a rise in free cytosolic calcium concentration. Nature (1987) 3.39
Association of lactoferrin with specific granules in rabbit heterophil leukocytes. J Exp Med (1970) 3.32
Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J Exp Med (1996) 3.30
A human serum immunoglobulin with specificity for certain homologous target cells, which induces target cell damage by normal human lymphocytes. Immunology (1969) 3.12
Antigen-driven selection of virgin and memory B cells. Immunol Rev (1986) 3.10
Further biochemical and morphological studies of granule fractions from rabbit heterophil leukocytes. J Cell Biol (1970) 3.06
Phagocytosing neutrophils produce and release high amounts of the neutrophil-activating peptide 1/interleukin 8. J Exp Med (1991) 2.96
Effect of specific antibody to target cells on their specific and non-specific interactions with lymphocytes. Nature (1968) 2.96
Mechanism of neutrophil activation by NAF, a novel monocyte-derived peptide agonist. FASEB J (1988) 2.83
Competition for receptors for immunoglobulin on cytotoxic lymphocytes. Clin Exp Immunol (1972) 2.77
The first external domain of the nonobese diabetic mouse class II I-A beta chain is unique. Proc Natl Acad Sci U S A (1987) 2.77
Germinal center cells express bcl-2 protein after activation by signals which prevent their entry into apoptosis. Eur J Immunol (1991) 2.71
Subcellular localization and heterogeneity of neutral proteases in neutrophilic polymorphonuclear leukocytes. J Exp Med (1975) 2.64
Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-/- mice. Science (1992) 2.60
IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity (1997) 2.54
HIV blocked by chemokine antagonist. Nature (1996) 2.50
Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes. Eur J Immunol (1995) 2.48
Germinal centres in T-cell-dependent antibody responses. Immunol Today (1992) 2.47
Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J Exp Med (1991) 2.46
CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1. J Exp Med (1998) 2.45
Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8. Proc Natl Acad Sci U S A (1993) 2.45
Neutrophil-activating protein 1/interleukin 8 stimulates the binding activity of the leukocyte adhesion receptor CD11b/CD18 on human neutrophils. J Exp Med (1990) 2.42
In vivo inflammatory activity of neutrophil-activating factor, a novel chemotactic peptide derived from human monocytes. Am J Pathol (1989) 2.37
Subcellular localization of the superoxide-forming enzyme in human neutrophils. J Clin Invest (1979) 2.33
Secretion of lysosomal hydrolases by stimulated and nonstimulated macrophages. J Exp Med (1978) 2.32
Neutrophil activation by monomeric interleukin-8. Science (1994) 2.31
Complement facilitates early prion pathogenesis. Nat Med (2001) 2.30
Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil-activating chemokine. J Exp Med (1994) 2.29
Monocyte chemotactic proteins MCP-1, MCP-2, and MCP-3 are major attractants for human CD4+ and CD8+ T lymphocytes. FASEB J (1994) 2.27
Memory B cells in T cell-dependent antibody responses colonize the splenic marginal zones. Eur J Immunol (1988) 2.26
Neutrophil chemotactic factor (IL-8) gene expression by cytokine-treated retinal pigment epithelial cells. Am J Pathol (1990) 2.25
Germinal centers without T cells. J Exp Med (2000) 2.25
Release of gelatinase from a novel secretory compartment of human neutrophils. J Clin Invest (1982) 2.21
Chemical synthesis, purification, and characterization of two inflammatory proteins, neutrophil activating peptide 1 (interleukin-8) and neutrophil activating peptide. Biochemistry (1991) 2.20
Immunoglobulin switch transcript production in vivo related to the site and time of antigen-specific B cell activation. J Exp Med (1996) 2.18
Neutrophil-activating properties of the melanoma growth-stimulatory activity. J Exp Med (1990) 2.17
The changing preference of T and B cells for partners as T-dependent antibody responses develop. Immunol Rev (1997) 2.16
Structure-activity relationships of chemokines. J Leukoc Biol (1995) 2.15
The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7. Eur J Immunol (1998) 2.15
The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4. Eur J Immunol (1997) 2.14
Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-alpha and interleukin 1. Proc Natl Acad Sci U S A (1990) 2.13
Superantigen-induced immune stimulation amplifies mouse mammary tumor virus infection and allows virus transmission. Cell (1993) 2.11
Recombinant human MCP-1/JE induces chemotaxis, calcium flux, and the respiratory burst in human monocytes. Blood (1991) 2.10
Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg. Proc Natl Acad Sci U S A (1993) 2.09
High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines. J Clin Invest (1997) 2.09
Marginal zones: the major B cell compartment of rat spleens. Eur J Immunol (1981) 2.08
Efficient interaction of HIV-1 with purified dendritic cells via multiple chemokine coreceptors. J Exp Med (1996) 2.08
T cell recognition as the target for immune intervention in autoimmune disease. Cell (1989) 2.04
Enhanced production of neutrophil-activating peptide-1/interleukin-8 in rheumatoid arthritis. J Clin Invest (1991) 2.04
Cytotoxic lymphocytes from rats depleted of thymus processed cells. Nat New Biol (1971) 2.02
Activation of NK cells by CC chemokines. Chemotaxis, Ca2+ mobilization, and enzyme release. J Immunol (1996) 1.99
Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med (2000) 1.99
Effects of the neutrophil-activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide III and platelet factor 4 on human neutrophils. J Exp Med (1989) 1.98
Human alveolar macrophage gene expression of interleukin-8 by tumor necrosis factor-alpha, lipopolysaccharide, and interleukin-1 beta. Am J Respir Cell Mol Biol (1990) 1.98
The role of immunoglobulins in lymphocyte-mediated cell damage, in vitro. II. The mechanism of target cell damage by lymphoid cells from immunized rats. Immunology (1970) 1.96
BCA-1 is highly expressed in Helicobacter pylori-induced mucosa-associated lymphoid tissue and gastric lymphoma. J Clin Invest (1999) 1.94
The interleukin-8-related chemotactic cytokines GRO alpha, GRO beta, and GRO gamma activate human neutrophil and basophil leukocytes. J Biol Chem (1993) 1.92
T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching. J Exp Med (1998) 1.91
Predominant expression of a T cell receptor V beta gene subfamily in autoimmune encephalomyelitis. J Exp Med (1988) 1.89
Distinct short-lived and long-lived antibody-producing cell populations. Eur J Immunol (1986) 1.89
Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell survival. J Exp Med (2000) 1.87
The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J Biol Chem (2000) 1.86
Assay of H2O2 production by macrophages and neutrophils with homovanillic acid and horse-radish peroxidase. J Immunol Methods (1983) 1.85
Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest (2001) 1.84
Neutrophil-activating peptide 2 and gro/melanoma growth-stimulatory activity interact with neutrophil-activating peptide 1/interleukin 8 receptors on human neutrophils. J Biol Chem (1991) 1.83
Recombinant 25-kDa CD23 and interleukin 1 alpha promote the survival of germinal center B cells: evidence for bifurcation in the development of centrocytes rescued from apoptosis. Eur J Immunol (1991) 1.82